Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.

Agarwal A, Kumar S, Narang J, Schultz L, Mikkelsen T, Wang S, Siddiqui S, Poptani H, Jain R.

J Neurooncol. 2013 May;112(3):413-20. doi: 10.1007/s11060-013-1070-1. Epub 2013 Feb 18.

PMID:
23417357
2.

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.

Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T.

Neuro Oncol. 2016 Oct;18(10):1434-41. doi: 10.1093/neuonc/now091. Epub 2016 Aug 11.

3.
4.

Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

Chu HH, Choi SH, Ryoo I, Kim SC, Yeom JA, Shin H, Jung SC, Lee AL, Yoon TJ, Kim TM, Lee SH, Park CK, Kim JH, Sohn CH, Park SH, Kim IH.

Radiology. 2013 Dec;269(3):831-40. doi: 10.1148/radiol.13122024. Epub 2013 Oct 28.

PMID:
23771912
5.

Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.

Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ.

AJNR Am J Neuroradiol. 2015 May;36(5):877-85. doi: 10.3174/ajnr.A4218. Epub 2015 Jan 15.

6.

Differentiation of true-progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide by GLCM texture analysis of conventional MRI.

Chen X, Wei X, Zhang Z, Yang R, Zhu Y, Jiang X.

Clin Imaging. 2015 Sep-Oct;39(5):775-80. doi: 10.1016/j.clinimag.2015.04.003. Epub 2015 Apr 16.

PMID:
25956436
7.

Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.

Wang S, Martinez-Lage M, Sakai Y, Chawla S, Kim SG, Alonso-Basanta M, Lustig RA, Brem S, Mohan S, Wolf RL, Desai A, Poptani H.

AJNR Am J Neuroradiol. 2016 Jan;37(1):28-36. doi: 10.3174/ajnr.A4474. Epub 2015 Oct 8.

8.

Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.

Thompson EM, Dosa E, Kraemer DF, Neuwelt EA.

J Neurooncol. 2011 Jun;103(2):353-60. doi: 10.1007/s11060-010-0397-0. Epub 2010 Sep 17.

PMID:
20848300
9.

Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.

Rowe LS, Butman JA, Mackey M, Shih JH, Cooley-Zgela T, Ning H, Gilbert MR, Smart DK, Camphausen K, Krauze AV.

J Neurooncol. 2018 May 16. doi: 10.1007/s11060-018-2855-z. [Epub ahead of print]

PMID:
29767308
10.

Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.

Lee WJ, Choi SH, Park CK, Yi KS, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH.

Acad Radiol. 2012 Nov;19(11):1353-61. doi: 10.1016/j.acra.2012.06.011. Epub 2012 Aug 11.

PMID:
22884399
11.

Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.

Thomas AA, Arevalo-Perez J, Kaley T, Lyo J, Peck KK, Shi W, Zhang Z, Young RJ.

J Neurooncol. 2015 Oct;125(1):183-90. doi: 10.1007/s11060-015-1893-z. Epub 2015 Aug 15.

12.

Voxel-based clustered imaging by multiparameter diffusion tensor images for glioma grading.

Inano R, Oishi N, Kunieda T, Arakawa Y, Yamao Y, Shibata S, Kikuchi T, Fukuyama H, Miyamoto S.

Neuroimage Clin. 2014 Aug 7;5:396-407. doi: 10.1016/j.nicl.2014.08.001. eCollection 2014.

13.

Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.

Yoo RE, Choi SH, Kim TM, Lee SH, Park CK, Park SH, Kim IH, Yun TJ, Kim JH, Sohn CH.

AJNR Am J Neuroradiol. 2015 Oct;36(10):1846-52. doi: 10.3174/ajnr.A4401. Epub 2015 Aug 20.

14.

ADC texture--an imaging biomarker for high-grade glioma?

Brynolfsson P, Nilsson D, Henriksson R, Hauksson J, Karlsson M, Garpebring A, Birgander R, Trygg J, Nyholm T, Asklund T.

Med Phys. 2014 Oct;41(10):101903. doi: 10.1118/1.4894812.

PMID:
25281955
15.

Hypercellularity Components of Glioblastoma Identified by High b-Value Diffusion-Weighted Imaging.

Pramanik PP, Parmar HA, Mammoser AG, Junck LR, Kim MM, Tsien CI, Lawrence TS, Cao Y.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):811-9. doi: 10.1016/j.ijrobp.2015.02.058. Epub 2015 Mar 26.

16.

Comparison of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT for the detection of recurrent high-grade glioma.

Alexiou GA, Zikou A, Tsiouris S, Goussia A, Kosta P, Papadopoulos A, Voulgaris S, Tsekeris P, Kyritsis AP, Fotopoulos AD, Argyropoulou MI.

Magn Reson Imaging. 2014 Sep;32(7):854-9. doi: 10.1016/j.mri.2014.04.013. Epub 2014 Apr 24.

PMID:
24848292
17.

MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study.

Vrabec M, Van Cauter S, Himmelreich U, Van Gool SW, Sunaert S, De Vleeschouwer S, Suput D, Demaerel P.

Neuroradiology. 2011 Oct;53(10):721-31. doi: 10.1007/s00234-010-0802-6. Epub 2010 Nov 25.

PMID:
21107549
18.

Evaluating changes in tumor volume using magnetic resonance imaging during the course of radiotherapy treatment of high-grade gliomas: Implications for conformal dose-escalation studies.

Tsien C, Gomez-Hassan D, Ten Haken RK, Tatro D, Junck L, Chenevert TL, Lawrence T.

Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):328-32.

PMID:
15890571
19.

Pseudo progression identification of glioblastoma with dictionary learning.

Zhang J, Yu H, Qian X, Liu K, Tan H, Yang T, Wang M, Li KC, Chan MD, Debinski W, Paulsson A, Wang G, Zhou X.

Comput Biol Med. 2016 Jun 1;73:94-101. doi: 10.1016/j.compbiomed.2016.03.027. Epub 2016 Apr 1.

20.

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.

Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, Pope WB, Safran H.

Am J Clin Oncol. 2017 Jun;40(3):228-234. doi: 10.1097/COC.0000000000000156.

PMID:
25436828

Supplemental Content

Support Center